clinical trial · NCT07028268
A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.·phase2·recruiting·n = 210
For Prevention of Bone Events in Patients With Bone Metastases From Solid TumorsSHR-2017、Denosumab placeboSHR-2017、Denosumab placeboDenosumab；SHR-2017 placebo
brief summary
The study is being conducted to evaluate the efficacy, and safety of SHR-2017 Injection in Patients with Bone Metastases from Solid Tumors. To explore the reasonable dosage of SHR-2017 Injection for Bone Metastases from Solid Tumors
started
Jun 24, 2025
primary completion
Dec 1, 2025
completion
May 1, 2027
last updated
Dec 31, 2025
official title
A Multicenter, Randomized, Double-Blind, Positively Controlled Phase II Clinical Study Evaluating the Efficacy and Safety of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol